G1 THERAPEUTICS, INC. GTHX Income Statement

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Sep'16	Jun'16
Operating expenses
Research and development
20,434	24,492	22,941	23,489	18,080	19,078	15,873	18,385	17,347	15,076	14,054	13,667	11,084	5,695	6,454
General and administrative
11,387	12,061	11,083	9,094	7,801	7,008	4,949	3,268	3,378	2,206	1,875	1,712	1,294	918	975
Total operating expenses
31,821	36,553	34,024	32,583	25,881	26,086	20,822	21,653	20,725	17,282	15,929	15,379	12,378	6,613	7,429
Operating loss
-31,821	-36,553	-34,024	-32,583	-25,881	-26,086	-20,822	-21,653	-20,725	-17,282	-15,929	-15,379	-12,378	-6,613	-7,429
Other income (expense)
Other income
798	1,112	1,660	1,893	1,929	1,994	904	785	315	301	328	185	74	56	50
Change in fair value in warrant liability and other liabilities
-	-	-	-	-	-	-	-	-	0	0	0	41	-	-
Total other income, net
798	1,112	1,660	1,893	1,929	1,994	904	785	315	301	328	185	33	56	50
Net loss
-31,023	-35,441	-32,364	-30,690	-23,952	-24,092	-19,918	-20,868	-20,410	-16,981	-15,601	-15,194	-12,345	-6,557	-7,379
Accretion of redeemable convertible preferred stock
-	-	-	-	-	-	-	-	-	0	0	289	4,468	1,205	986
Net loss attributable to common stockholders
-31,023	-35,441	-	-	-23,952	-24,092	-	-	-20,410	-16,981	-15,601	-15,483	-16,813	-7,762	-8,365
Net loss per share attributable to common stockholders, basic and diluted
-0.82	-0.94	-0.86	-0.82	-0.64	-0.65	-0.59	-0.64	-0.70	9.31	-0.55	-1.09	-11.24	-5.21	-5.63
Weighted average common shares outstanding, basic and diluted
37,659	37,586	37,540	37,470	37,396	37,203	33,829	32,781	29,360	28,768	28,318	14,208	1,496	1,490	1,486